Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate the effect of sitagliptin on overall blood glucose concentrations in Type I Diabetic subjects. The study also aims to evaluate post meal glucagon concentrations in Type I Diabetic subjects (a possible mechanism of reduced blood glucose concentrations) and indices of oxidation stress in the plasma of these subjects.


Clinical Trial Description

The hypothesis is that Sitagliptin will improve overall blood glucose, fasting blood glucose, and glycemic excursions in patients with Type I Diabetes. In addition, sitagliptin will likely suppress indices of oxidative stress in patients. The study will investigate proposed mechanisms of improved glucose concentrations, including enhanced effect of endogenous GLP-1 and suppression of glucagon. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01741103
Study type Interventional
Source University at Buffalo
Contact
Status Withdrawn
Phase N/A
Start date June 2011
Completion date September 2013

See also
  Status Clinical Trial Phase
Completed NCT02184455 - Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment Phase 1